[Pharmacologic effects of the antihypertensive 6-benzoyl-3-hydrazino-5,6,7,8-tetrahydropyrido[4,3-c]pyridazine (BQ 22-708, endralazine)].
D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001679:Biogenic Amines / Q000378:metabolism; D002319:Cardiovascular System / Q000187:drug effects; D002415:Cats; D004285:Dogs; D006439:Hemodynamics / Q000187:drug effects; D007668:Kidney / Q000187:drug effects; D008297:Male; D008995:Monoamine Oxidase / Q000378:metabolism; D009119:Muscle Contraction / Q000187:drug effects; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism; D011724:Pyridazines / Q000494:pharmacology*; D051381:Rats; D012083:Renin / Q000097:blood; D013564:Sympathetic Nervous System / Q000187:drug effects; D013997:Time Factors
D000959:Antihypertensive Agents; D001679:Biogenic Amines; D011724:Pyridazines; C014926:BQ 22-708; D008995:Monoamine Oxidase; D010727:Phosphoric Diester Hydrolases; D012083:Renin
Pharmakologische Wirkungen des Antihypertensivums 6-Benzoyl-3-hydrazino-5,6,7,8-tetrahydropyrido[4,3-c]pyridazin (BQ 22-708, Endralazin).